1.
几项胸腺瘤化疗的试验结果
Results of several trials about chemotherapy efficacy in thymoma
| Author | Regimen | Number of patients (n) | Response rate (%) | MST(year) |
| PAC: cisplatin+adriamycin+cyclophosphamide; ADOC: cisplatin+adriamycin+vincristine+cyclophosphamide; PE: cisplatin+etoposide; VIP: ifosfamide+etoposide+cisplatin; CAMP: cispaltin+adriamycin+methylprednisolone; MST: median survival time; NR: not report. | ||||
| Loehrer[23] | PAC (cisplatin 50mg/m2, d1; adriamycin 50mg/m2, d1; cyclophosphamide 500 mg/m2, d1; q3 weeks) | 30 | 50 | 3.2 |
| Fornasiero[24] | ADOC (cisplatin 50 mg/m2, d1; adriamycin 40 mg/m2, d1; vincristine 0.6 mg/m2, d3; cyclophosphamide 700 mg/m2, d4; q4 weeks) | 32 | 92 | 1.25 |
| Giacone[25] | PE (cisplatin 60 mg/m2, d1; etoposide 120 mg/m2, d1-d3; q3 weeks) | 16 | 56 | 4.3 |
| Loehrer[26] | VIP (etoposide 75 mg/m2, d1-d4; ifosfamide 1.2 g/m2, d1-d4; cisplatin 20 mg/m2, d1-d4; q3 weeks) | 28 | 32 | 2.7 |
| Lemma[27] | PC (paclitaxel 225 mg/m2, carboplatin AUC 5, q3 weeks) | 24 | 33 | > 5 |
| Yokoi[28] | CAMP (cisplatin 20 mg/m2, d1-d4; adriamycin 40 mg/m2, d1; methylprednisolone 1 000 mg/d, d1-d4, 500 mg/d, d5-d6; q3-4 weeks) | 14 | 93 | NR |